Multiple Myeloma section

Multiple Myeloma News & Features

Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma

Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma

Ixazomib, a new proteasome inhibitor (PI), is a third option for the treatment of relapsed/refractory multiple myeloma (RRMM) offering the potential of improved efficacy and the convenience of oral therapy.

Type and Crossmatch Needed Before Initiating Treatment With Daratumumab

Type and Crossmatch Needed Before Initiating Treatment With Daratumumab

Why is a type and crossmatch needed before starting patients on treatment with daratumumab (Darzalex)?

ASCO: CAR T-Cell Therapy Promising for Multiple Myeloma

ASCO: CAR T-Cell Therapy Promising for Multiple Myeloma

Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein demonstrated promising results.

Costs High for Myeloma Patients Not Getting Low-Income Subsidy

Costs High for Myeloma Patients Not Getting Low-Income Subsidy

For those aged 75 to 84 years, LIS receipt linked to increased odds of receiving immunomodulatory drugs

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs